- Home
- FE vs BDTX Comparison
FE vs BDTX Comparison
Compare FE & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | BDTX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FE | BDTX |
|---|---|---|
| Price | $44.20 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $48.67 | $10.60 |
| AVG Volume (30 Days) | ★ 4.9M | 1.6M |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ 48.81 | N/A |
| EPS | ★ 2.31 | 0.38 |
| Revenue | ★ $14,283,000,000.00 | $70,000,000.00 |
| Revenue This Year | $10.15 | N/A |
| Revenue Next Year | $3.69 | N/A |
| P/E Ratio | $19.09 | ★ $6.93 |
| Revenue Growth | ★ 7.74 | N/A |
| 52 Week Low | $37.58 | $1.20 |
| 52 Week High | $48.20 | $4.94 |
Technical Indicators
Market Signals| Indicator | FE | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 31.24 |
| Support Level | $43.88 | $2.59 |
| Resistance Level | $44.72 | $2.84 |
| Average True Range (ATR) | 0.69 | 0.25 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 8.82 | 25.30 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.